Publication – Neurological Disorders

Menalled L, Brunner D.
Animal Models of Huntington’s Disease for Translation to the Clinic: Best Practices. Movement Disorders 29(11): 1375-90 2014

Menalled L, Kudwa A, Oakeshott S, Farrar A, Paterson N, Filippov I, Miller S, Kwan M, Olsen M, Beltran J, Torello J, Fitzpatrick J, Mushlin R, Cox K, McConnell K, Mazzella M, He D, Osborne GF, Al-Nackkash R, Bates GP, Tuunanen P, Lehtimaki K, Brunner D, Ghavami A, Ramboz S, Park L, Macdonald D, Munoz-Sanjuan I and Howland D
Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington’s disease.PLOS ONE 2014

Balci F, Oakeshott S, Shamy J.S., El-Khodor B.F., Filippov I, Mushlin R, Port R, Connor D, Paintdakhi A, Menalled L, Ramboz S, Howland D, Kwa S, Brunner D
High-Throughput Automated Phenotyping of Two Genetic Mouse Models of Huntington’s Disease. July 2013

Moreno H, Lewandowski N, Bordelon Y, Brickman A, Angulo S, Khan U, Muraskin J, Griffith E, Wasserman P, Menalled L, Vonsattel J.P, Marder K, Small S.A
Regional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease. Neurobiology of Disease. 2013

Menalled L, Kudwa A, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, Ruiz M, Mushlin R, Alosio B, McConnell K, Connor D, Murphy C, Oakeshott S, Kwan M, Beltran J, Ghavami A, Brunner D, C. Park L, Ramboz S and Howland D
Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: zQ175 . 2012

S. Stefanie, H Bettina, Nilges M, Schroeder S, Hoelich A, Keletzl H, Spooren W, Ostrowitzki S, Hanania T, Sendtner M, Metzger F.
Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity . 2012

El-Khodor BF, Cirillo K, Beltran JA, Mushlin R, Winberg ML, Charney R, Chomicova O, Marino T, Ramboz S.
Prediction of Death in the SMNΔ 7 Mouse Model of Spinal Muscular Atrophy: Insight into Disease Stage and Progression. Journal of Neuroscience Methods. 2012

Menalled, L., El-Khodor, B. F., Hornberger, M., Park, L., Howland, D., and Brunner, D.
Effect of the rd1 mutation on motor performance in R6/2 and wild type mice, in PLoS Currents Huntington Disease.. 2012.

Chen P.C, Gaisina I.N, El-Khodor B.F, Ramboz S, Makhortova N.R, Rubin L.L, Kozikowski A.P.
Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, that Prolongs the Median Survival Time of Ä7 SMA KO Mouse Model of Spinal Muscular Atrophy. ACS Chem Neurosci. 2012 Jan 18;3(1):5-11.

Gafni J, Papanikolaou T, DeGiacomo F, Holcomb J, Chen S, Menalled L, Kudwa A, Fitzpatrick J, Miller S, Ramboz S, Tuunanen P, Lehtimaki K, William Y.X, Kwak S, Park L, Howland D, Park H, Ellerby L
Caspase-6 activity in a BAC HD mouse modulates steady state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. 2012 JN-RM-6379-11R1

Cepeda-Prado E, Popp S, Khan U, Stefanov D, Rodrguez J, Menalled L, Dow-Edwards D, Small S, Moreno H
R6/2 Huntington's disease Mice Develop Early and Progressive Abnormal Brain Metabolism and Seizures. 2012 JN-RM-0388-12R1

Oakeshott S, Balci F, Filippov I, Murphy C, Port R, Connor D, Paintdakhi A, Lesauter J, Menalled L, Ramboz S, Kwak S, Howland D, Silver R, Brunner D.
Circadian Abnormalities in Motor Activity in a BAC Transgenic Mouse Model of Huntington's Disease.2011Apr 5;3:RRN1225

Brunner D, Balci F, Ludvig E.A.
Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration, Behav Processes 2011 89, 187-195

Menalled L, El-Khodor B.F, Hornberger M, Park Lm Howland Dm Brunner D.
Effect of the rd1 mutation on motor performance in R6/2 and wild type mice [Internet]. Version 28. PLoS Currents: Huntington Disease. 2011 Nov 29 [revised 2012 Feb 15].

Oakeshott S, Balci F, Filippov I, Murphy C, Port R, Connor D, Paintdakhi A, Lesauter J, Menalled L, Ramboz S, Kwak S, Howland D, Silver R, Brunner D.
Circadian Abnormalities in Motor Activity in a BAC Transgenic Mouse Model of Huntington's Disease. PLoS Curr 2011, 3, RRN1225.

Menalled L.B, Patry M, Ragland N, Lowden P.A, Goodman J, Minnich J, Zahasky B, Park L, Leeds J, Howland D, Signer E, Tobin A.J, Brunner D.
Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One 2010, 5, e9793.

Baker K, Wray S, Ritter R, Mason S, Lanthorn T, Savelieva K.
Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments. Genes, Brain and Behavior 2010, 9, 562-574.

Marcellino D, Suárez-Boomgaard D, Sánchez-Reina M.D, Aguirre J.A, Yoshitake T, Yoshitake S, Hagman B, Kehr J, Agnati L.F, Fuxe K, Rivera A.
On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079. J Neural Transm 2010, 117, 681-687.

Galter D, Pernold K, Yoshitake T, Lindqvist E, Kehr J, Olson L.
MitoPark mice mirror the slow progression of key Parkinson disease symptoms and the L-DOPA response. Genes, Brain and Behavior 2010, 9, 173-181.

Paterson N.E, Malekiani S.A, Foreman M.M, Olivier B, Hanania T.
Pharmacological characterization of harmaline-induced tremor activity in mice. Eur J Pharmacol 2009, 616, 73-80.

Menalled L, El-Khodor B.F, Patry M, Suarez-Farinas M, Orenstein S.J, Zahasky B, Leahy C, Wheeler V, Yang X.W, MacDonald M, Morton A.J, Bates G, Leeds J, Park L, Howland D, Signer E, Tobin A, Brunner D.
Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis 2009, 35, 319-36.

Balci F, Moore H, Brunner D.
Timing Deficits in Neuropathology In Cognitive Aging: Integrating Models. Humana Press: Wagner, L.A., 2008.

El-Khodor B.F, Edgar N, Chen A, Winberg M.L, Joyce C, Brunner D, Suarez-Farinas M, Heyes M.P.
Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy. Exp Neurol 2008, 212, 29-43.

Menalled L, Gomeniouk A, Brunner D, Leavitt B.R.
Huntington Disease In Animal and Translational Models of Behavioral Disorders Borsini, R. M. a. F., Ed. Elsevier: 2008.

Roy K, Murtie J.C, El-Khodor B.F, Edgar N, Sardi S.P, Hooks B.M, Benoit-Marand M, Chen C, Moore H, O'Donnell P, Brunner D, Corfas G.
Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proc Natl Acad Sci U S A 2007, 104, 8131-6.

Herrera-Marschitz M, Bustamante D, Morales P, Goiny M.
Exploring neurocircuitries of the basal ganglia by intracerebral administration of selective neurotoxins. Neurotox Res 2007, 11(3-4), 169-82.

Kehr J, Hu X.J, Goiny M, Scheller D.K.
Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. J Neural Transm 2007, 114, 1027-1031.

Kehr J, Hu X.J, Yoshitake T, Scheller D.
Determination of the dopamine agonist rotigotine in microdialysates from the rat brain by microbore column liquid chromatography with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 845, 109-113.

Menalled L.
Knock-in mouse models of Huntington's disease>. NeuroRx 2005, 2, 465-70.

Aguirre J.A, Kehr J, Yoshitake T, Liu F.L, Rivera A, Fernandez-Espinola S, Andbjer B, Leo G, Medhurst A.D, Agnati L.F, Fuxe K.
Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res 2005, 1033, 216-20.

Tanganelli S, Sandager N.K, Ferraro L, Antonelli T, Kehr J, Franco R, Ferre S, Agnati L.F, Fuxe K, Scheel-Kruger J.
Striatal plasticity at the network level. Focus on adenosine A(2A) and D(2) interactions in models of Parkinson's Disease. Parkinsonism Relat Disord 2004, 10, 273-80.

Bustamante D, Bustamante L, Segura-Aguilar J, Goiny M, Herrera-Marschitz M.
Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats. Neurotox Res. 2004 5(8):569-77


  • PsychoGenics
  • 765 Old Saw Mill River Road, Tarrytown, NY 10591
  • tel: (914) 406-8019
  • fax: (914) 593-0645